Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial

Fig. 3

Biomarker analysis stratified by the baseline levels of Ki-67, NSE, ProGRP, and the status of PD-L1 expression & TMB. Tumor shrinkage rate and Kaplan–Meier curves of PFS & OS stratified by the baseline levels of a Ki-67, b NSE, c ProGRP. d Swimmer plot stratified by the status of PD-L1 expression and TMB at baseline

Back to article page